Guanfacine and meditation with buprenorphine for opioid use disorder
Part of Mental health clinical trials.
This study tests if adding a medication called guanfacine and mindfulness meditation to standard buprenorphine treatment helps people with opioid use disorder. It looks at whether this combination can improve treatment outcomes and reduce opioid use.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 55 years old.
- You have been taking buprenorphine for at least 4 weeks.
- Your body mass index (BMI) is between 18 and 35.
- You have a positive urine test for opioids that were not prescribed to you.
- You are generally healthy and can read English.
- You are not pregnant or nursing, and agree to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two different forms of buprenorphine (a medication for opioid addiction) to see which works better for people who use fentanyl or other strong synthetic opioids. If you are seeking treatment for opioid use, this trial may help you find the most effective option.
This study uses MRI scans over time to track brain changes in people with opioid use disorder who recently started methadone treatment. You can help researchers understand recovery patterns if you are early in your methadone journey and can commit to repeated visits.
This study tests if combining ketamine with a mindfulness program can help people who are still struggling with opioid use while on buprenorphine. If you are already taking buprenorphine but still using opioids, this treatment may offer additional support to help you stop.
This study compares two medications, methadone and buprenorphine, to see which helps people stay in treatment for opioid use disorder. You may be eligible if you are starting a new treatment episode.
This Phase 1 study tests how adding psilocybin to a standard opioid treatment (buprenorphine-naloxone) affects recovery and symptoms in people with moderate-to-severe opioid use disorder. It may help researchers understand whether this combination is safe and beneficial alongside medication for opioid withdrawal and cravings.
This trial tests if brain stimulation can help people starting buprenorphine for opioid use disorder. It aims to improve treatment outcomes and support recovery.
Hear when a new Mindfulness trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.